Kyle T. Cunningham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kyle T. Cunningham has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Rick M. Maizels
University of Glasgow
6 shared publications - Andrew P. Hinck
University of Pittsburgh
4 shared publications - Ananya Mukundan
Department of Structural Biology University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA
3 shared publications Claire Ciancia
Centre for Parasitology, School of Infection and Immunity University of Glasgow Glasgow UK
3 shared publications- Kingston H. G. Mills
Immune Regulation Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
3 shared publications - Peter Ten Dijke
Oncode Institute and Department of Cell and Chemical Biology Leiden University Medical Center Leiden The Netherlands
3 shared publications
Latest Publications
- Open Access
- 31 March 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (7) , e71338
Molecular Engineering of the Helminth TGF ‐β Mimetics, TGM1 and TGM4, Reveals a Novel Antagonist of TGF ‐β Signaling in Fibroblasts
The transforming growth factor‐β (TGF‐β) mimics TGM1 and TGM4 are modular proteins expressed by the parasite Heligmosomoides polygyrus . Each comprises 5 complement control protein (CCP) domains binding the TGF‐β receptors TGFBR1 (Domains 1 and 2) and TGFBR2 (Domain 3), whereas Domains 4 and 5 bind cell surface co‐receptors including CD44. Despite sharing 86% amino acid identity, TGM1 and TGM4 differ functionally in key respects of affinity for mammalian TGFBRs and interactions with cell surface co‐receptors. Although both induce T cell expression of the transcription factor Foxp3, TGM1 activates intracellular SMAD signaling in fibroblasts, whereas conversely, TGM4 blocks SMAD responses to TGF‐β or TGM1 in fibroblasts. By recombining and/or deleting domains, we identified that the TGFBR1‐binding Domains 1 and 2 of TGM4 confer antagonist activity, which is dependent on the CD44 co‐receptor interacting domains (Domains 4 and 5); antagonism is enhanced but not fully dependent on binding to TGFBR2. TGMs lack interchain disulfide bonds, in distinction to TGF‐β, which is a covalently linked dimeric cytokine. Dimerization of TGM4 as an Fc fusion protein converted it from an inhibitor to an activator of SMAD signaling in fibroblasts and enhanced Foxp3 induction, indicating that high avidity interactions (either monomer/dimer on T cells or only dimer on fibroblasts) drive TGF‐β signaling. However, when TGM4 is below an avidity threshold, it binds receptors in an antagonistic mode. These results advance our understanding of the mechanism of action of these parasite‐encoded products and uncover new tools modulating TGF‐β functions in health and disease.
- 31 March 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (7) , e71338
Open AccessMolecular Engineering of the Helminth TGF ‐β Mimetics, TGM1 and TGM4, Reveals a Novel Antagonist of TGF ‐β Signaling in Fibroblasts
The transforming growth factor‐β (TGF‐β) mimics TGM1 and TGM4 are modular proteins expressed by the parasite Heligmosomoides polygyrus . Each comprises 5 complement control protein (CCP) domains binding the TGF‐β receptors TGFBR1 (Domains 1 and 2) and TGFBR2 (Domain 3), whereas Domains 4 and 5 bind cell surface co‐receptors including CD44. Despite sharing 86% amino acid identity, TGM1 and TGM4 differ functionally in key respects of affinity for mammalian TGFBRs and interactions with cell surface co‐receptors. Although both induce T cell expression of the transcription factor Foxp3, TGM1 activates intracellular SMAD signaling in fibroblasts, whereas conversely, TGM4 blocks SMAD responses to TGF‐β or TGM1 in fibroblasts. By recombining and/or deleting domains, we identified that the TGFBR1‐binding Domains 1 and 2 of TGM4 confer antagonist activity, which is dependent on the CD44 co‐receptor interacting domains (Domains 4 and 5); antagonism is enhanced but not fully dependent on binding to TGFBR2. TGMs lack interchain disulfide bonds, in distinction to TGF‐β, which is a covalently linked dimeric cytokine. Dimerization of TGM4 as an Fc fusion protein converted it from an inhibitor to an activator of SMAD signaling in fibroblasts and enhanced Foxp3 induction, indicating that high avidity interactions (either monomer/dimer on T cells or only dimer on fibroblasts) drive TGF‐β signaling. However, when TGM4 is below an avidity threshold, it binds receptors in an antagonistic mode. These results advance our understanding of the mechanism of action of these parasite‐encoded products and uncover new tools modulating TGF‐β functions in health and disease.
- Open Access
- 28 November 2024
- Published by Springer Nature in EMBO Reports
- Vol. 26 (1) , 218-244
The TGF-β mimic TGM4 achieves cell specificity through combinatorial surface co-receptor binding
The immunoregulatory cytokine TGF-β is pleiotropic due to the near-ubiquitous expression of the TGF-β receptors TβRI and TβRII on diverse cell types. The helminth parasite Heligmosomoides polygyrus has convergently evolved a family of TGF-β mimics (TGMs) that bind both these receptors through domains 1–3 of a 5-domain protein. One member of this family, TGM4, differs from TGF-β in acting in a cell-specific manner, failing to stimulate fibroblasts, but activating SMAD phosphorylation in macrophages. Primarily through domains 4 and 5, TGM4 interacts with multiple co-receptors, including CD44, CD49d (integrin α4) and CD206, and can up- and downmodulate macrophage responses to IL-4 and lipopolysaccharide (LPS), respectively. The dependence of TGM4 on combinatorial interactions with co-receptors is due to a moderated affinity for TβRII that is more than 100-fold lower than for TGF-β. Thus the parasite has elaborated TGF-β receptor interactions to establish cell specificity through combinatorial cis -signalling, an innovation absent from the mammalian cytokine.
- 28 November 2024
- Published by Springer Nature in EMBO Reports
- Vol. 26 (1) , 218-244
Open AccessThe TGF-β mimic TGM4 achieves cell specificity through combinatorial surface co-receptor binding
The immunoregulatory cytokine TGF-β is pleiotropic due to the near-ubiquitous expression of the TGF-β receptors TβRI and TβRII on diverse cell types. The helminth parasite Heligmosomoides polygyrus has convergently evolved a family of TGF-β mimics (TGMs) that bind both these receptors through domains 1–3 of a 5-domain protein. One member of this family, TGM4, differs from TGF-β in acting in a cell-specific manner, failing to stimulate fibroblasts, but activating SMAD phosphorylation in macrophages. Primarily through domains 4 and 5, TGM4 interacts with multiple co-receptors, including CD44, CD49d (integrin α4) and CD206, and can up- and downmodulate macrophage responses to IL-4 and lipopolysaccharide (LPS), respectively. The dependence of TGM4 on combinatorial interactions with co-receptors is due to a moderated affinity for TβRII that is more than 100-fold lower than for TGF-β. Thus the parasite has elaborated TGF-β receptor interactions to establish cell specificity through combinatorial cis -signalling, an innovation absent from the mammalian cytokine.
- 20 May 2024
- Published by Elsevier in Trends in Parasitology
- Vol. 40 (6) , 446-448
We are what we eat: macrophages and efferocytosis
- 20 May 2024
- Published by Elsevier in Trends in Parasitology
- Vol. 40 (6) , 446-448
We are what we eat: macrophages and efferocytosis
- Open Access
- 6 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 743
Development of Good Manufacturing Practice-Compatible Isolation and Culture Methods for Human Olfactory Mucosa-Derived Mesenchymal Stromal Cells
Demyelination in the central nervous system (CNS) resulting from injury or disease can cause loss of nerve function and paralysis. Cell therapies intended to promote remyelination of axons are a promising avenue of treatment, with mesenchymal stromal cells (MSCs) a prominent candidate. We have previously demonstrated that MSCs derived from human olfactory mucosa (hOM-MSCs) promote myelination to a greater extent than bone marrow-derived MSCs (hBM-MSCs). However, hOM-MSCs were developed using methods and materials that were not good manufacturing practice (GMP)-compliant. Before considering these cells for clinical use, it is necessary to develop a method for their isolation and expansion that is readily adaptable to a GMP-compliant environment. We demonstrate here that hOM-MSCs can be derived without enzymatic tissue digestion or cell sorting and without culture antibiotics. They grow readily in GMP-compliant media and express typical MSC surface markers. They robustly produce CXCL12 (a key secretory factor in promoting myelination) and are pro-myelinating in in vitro rodent CNS cultures. GMP-compliant hOM-MSCs are comparable in this respect to those grown in non-GMP conditions. However, when assessed in an in vivo model of demyelinating disease (experimental autoimmune encephalitis, EAE), they do not significantly improve disease scores compared with controls, indicating further pre-clinical evaluation is necessary before their advancement to clinical trials.
- 6 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 743
Open AccessDevelopment of Good Manufacturing Practice-Compatible Isolation and Culture Methods for Human Olfactory Mucosa-Derived Mesenchymal Stromal Cells
Demyelination in the central nervous system (CNS) resulting from injury or disease can cause loss of nerve function and paralysis. Cell therapies intended to promote remyelination of axons are a promising avenue of treatment, with mesenchymal stromal cells (MSCs) a prominent candidate. We have previously demonstrated that MSCs derived from human olfactory mucosa (hOM-MSCs) promote myelination to a greater extent than bone marrow-derived MSCs (hBM-MSCs). However, hOM-MSCs were developed using methods and materials that were not good manufacturing practice (GMP)-compliant. Before considering these cells for clinical use, it is necessary to develop a method for their isolation and expansion that is readily adaptable to a GMP-compliant environment. We demonstrate here that hOM-MSCs can be derived without enzymatic tissue digestion or cell sorting and without culture antibiotics. They grow readily in GMP-compliant media and express typical MSC surface markers. They robustly produce CXCL12 (a key secretory factor in promoting myelination) and are pro-myelinating in in vitro rodent CNS cultures. GMP-compliant hOM-MSCs are comparable in this respect to those grown in non-GMP conditions. However, when assessed in an in vivo model of demyelinating disease (experimental autoimmune encephalitis, EAE), they do not significantly improve disease scores compared with controls, indicating further pre-clinical evaluation is necessary before their advancement to clinical trials.
- 11 October 2023
- Published by Elsevier in Trends in Parasitology
- Vol. 39 (12) , 973-981
Hydra at 21, key to the door for helminth researchers
- 11 October 2023
- Published by Elsevier in Trends in Parasitology
- Vol. 39 (12) , 973-981
Hydra at 21, key to the door for helminth researchers
- Open Access
- 17 August 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (34)
CD44 acts as a coreceptor for cell-specific enhancement of signaling and regulatory T cell induction by TGM1, a parasite TGF-β mimic
Long-lived parasites evade host immunity through highly evolved molecular strategies. The murine intestinal helminth, Heligmosomoides polygyrus , down-modulates the host immune system through release of an immunosuppressive TGF-β mimic, TGM1, which is a divergent member of the CCP (Sushi) protein family. TGM1 comprises 5 domains, of which domains 1-3 (D1/2/3) bind mammalian TGF-β receptors, acting on T cells to induce Foxp3 + regulatory T cells; however, the roles of domains 4 and 5 (D4/5) remain unknown. We noted that truncated TGM1, lacking D4/5, showed reduced potency. Combination of D1/2/3 and D4/5 as separate proteins did not alter potency, suggesting that a physical linkage is required and that these domains do not deliver an independent signal. Coprecipitation from cells treated with biotinylated D4/5, followed by mass spectrometry, identified the cell surface protein CD44 as a coreceptor for TGM1. Both full-length and D4/5 bound strongly to a range of primary cells and cell lines, to a greater degree than D1/2/3 alone, although some cell lines did not respond to TGM1. Ectopic expression of CD44 in nonresponding cells conferred responsiveness, while genetic depletion of CD44 abolished enhancement by D4/5 and ablated the ability of full-length TGM1 to bind to cell surfaces. Moreover, CD44-deficient T cells showed attenuated induction of Foxp3 by full-length TGM1, to levels similar to those induced by D1/2/3. Hence, a parasite protein known to bind two host cytokine receptor subunits has evolved a third receptor specificity, which serves to raise the avidity and cell type–specific potency of TGF-β signaling in mammalian cells.
- 17 August 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (34)
Open AccessCD44 acts as a coreceptor for cell-specific enhancement of signaling and regulatory T cell induction by TGM1, a parasite TGF-β mimic
Long-lived parasites evade host immunity through highly evolved molecular strategies. The murine intestinal helminth, Heligmosomoides polygyrus , down-modulates the host immune system through release of an immunosuppressive TGF-β mimic, TGM1, which is a divergent member of the CCP (Sushi) protein family. TGM1 comprises 5 domains, of which domains 1-3 (D1/2/3) bind mammalian TGF-β receptors, acting on T cells to induce Foxp3 + regulatory T cells; however, the roles of domains 4 and 5 (D4/5) remain unknown. We noted that truncated TGM1, lacking D4/5, showed reduced potency. Combination of D1/2/3 and D4/5 as separate proteins did not alter potency, suggesting that a physical linkage is required and that these domains do not deliver an independent signal. Coprecipitation from cells treated with biotinylated D4/5, followed by mass spectrometry, identified the cell surface protein CD44 as a coreceptor for TGM1. Both full-length and D4/5 bound strongly to a range of primary cells and cell lines, to a greater degree than D1/2/3 alone, although some cell lines did not respond to TGM1. Ectopic expression of CD44 in nonresponding cells conferred responsiveness, while genetic depletion of CD44 abolished enhancement by D4/5 and ablated the ability of full-length TGM1 to bind to cell surfaces. Moreover, CD44-deficient T cells showed attenuated induction of Foxp3 by full-length TGM1, to levels similar to those induced by D1/2/3. Hence, a parasite protein known to bind two host cytokine receptor subunits has evolved a third receptor specificity, which serves to raise the avidity and cell type–specific potency of TGF-β signaling in mammalian cells.
- Open Access
- 28 February 2023
- Published by Wiley in Parasite Immunology
- Vol. 45 (12) , e12975
Modulation of haematopoiesis by protozoal and helminth parasites
During inflammation, haematopoietic stem cells (HSCs) in the bone marrow (BM) and periphery rapidly expand and preferentially differentiate into myeloid cells that mediate innate immune responses. HSCs can be directed into quiescence or differentiation by sensing alterations to the haematopoietic niche, including cytokines, chemokines, and pathogen‐derived products. Most studies attempting to identify the mechanisms of haematopoiesis have focused on bacterial and viral infections. From intracellular protozoan infections to large multicellular worms, parasites are a global health burden and represent major immunological challenges that remain poorly defined in the context of haematopoiesis. Immune responses to parasites vary drastically, and parasites have developed sophisticated immunomodulatory mechanisms that allow development of chronic infections. Recent advances in imaging, genomic sequencing, and mouse models have shed new light on how parasites induce unique forms of emergency haematopoiesis. In addition, parasites can modify the haematopoiesis in the BM and periphery to improve their survival in the host. Parasites can also induce long‐lasting modifications to HSCs, altering future immune responses to infection, inflammation or transplantation, a term sometimes referred to as central trained immunity. In this review, we highlight the current understanding of parasite‐induced haematopoiesis and how parasites target this process to promote chronic infections.
- 28 February 2023
- Published by Wiley in Parasite Immunology
- Vol. 45 (12) , e12975
Open AccessModulation of haematopoiesis by protozoal and helminth parasites
During inflammation, haematopoietic stem cells (HSCs) in the bone marrow (BM) and periphery rapidly expand and preferentially differentiate into myeloid cells that mediate innate immune responses. HSCs can be directed into quiescence or differentiation by sensing alterations to the haematopoietic niche, including cytokines, chemokines, and pathogen‐derived products. Most studies attempting to identify the mechanisms of haematopoiesis have focused on bacterial and viral infections. From intracellular protozoan infections to large multicellular worms, parasites are a global health burden and represent major immunological challenges that remain poorly defined in the context of haematopoiesis. Immune responses to parasites vary drastically, and parasites have developed sophisticated immunomodulatory mechanisms that allow development of chronic infections. Recent advances in imaging, genomic sequencing, and mouse models have shed new light on how parasites induce unique forms of emergency haematopoiesis. In addition, parasites can modify the haematopoiesis in the BM and periphery to improve their survival in the host. Parasites can also induce long‐lasting modifications to HSCs, altering future immune responses to infection, inflammation or transplantation, a term sometimes referred to as central trained immunity. In this review, we highlight the current understanding of parasite‐induced haematopoiesis and how parasites target this process to promote chronic infections.
- Open Access
- 29 April 2022
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 298 (6) , 101994
Convergent evolution of a parasite-encoded complement control protein-scaffold to mimic binding of mammalian TGF-β to its receptors, TβRI and TβRII
- 29 April 2022
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 298 (6) , 101994
Open AccessConvergent evolution of a parasite-encoded complement control protein-scaffold to mimic binding of mammalian TGF-β to its receptors, TβRI and TβRII
- 1 April 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 206 (7) , 1618-1630
Helminth Imprinting of Hematopoietic Stem Cells Sustains Anti-Inflammatory Trained Innate Immunity That Attenuates Autoimmune Disease
Certain proinflammatory stimuli can metabolically and epigenetically modify monocytes/macrophages or NK cells to be more responsive to secondary stimuli, a process known as trained innate immunity. However, the longevity of trained innate immunity is unclear. In this study, we report that Fasciola hepatica excretory-secretory products (FHES) can imprint an anti-inflammatory phenotype on long-term hematopoietic stem cells (HSCs) and monocyte precursor populations, enhancing their proliferation and differentiation into anti-inflammatory Ly6Clow monocytes. These monocytes expand and populate multiple compartments within mice, conferring hyporesponsiveness to proinflammatory stimuli and reduced susceptibility to induction of experimental autoimmune encephalomyelitis. Mice treated with FHES had enhanced alternatively activated macrophages, reduced Th1 and Th17 responses, and attenuating effects on autoimmunity that persisted for 8 mo. Furthermore, transplantation of HSCs from FHES-treated mice transferred the anti-inflammatory phenotype to naive mice. Our findings demonstrate that helminth products can modulate HSCs to promote development of anti-inflammatory myeloid cells that attenuate T cell–mediated autoimmune disease. Key Points Helminth products imprint long-term hematopoietic stem cells. Helminth-imprinted hematopoietic stem cells generate anti-inflammatory macrophages. Helminths attenuate autoimmunity by promoting anti-inflammatory trained immunity.
- 1 April 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 206 (7) , 1618-1630
Helminth Imprinting of Hematopoietic Stem Cells Sustains Anti-Inflammatory Trained Innate Immunity That Attenuates Autoimmune Disease
Certain proinflammatory stimuli can metabolically and epigenetically modify monocytes/macrophages or NK cells to be more responsive to secondary stimuli, a process known as trained innate immunity. However, the longevity of trained innate immunity is unclear. In this study, we report that Fasciola hepatica excretory-secretory products (FHES) can imprint an anti-inflammatory phenotype on long-term hematopoietic stem cells (HSCs) and monocyte precursor populations, enhancing their proliferation and differentiation into anti-inflammatory Ly6Clow monocytes. These monocytes expand and populate multiple compartments within mice, conferring hyporesponsiveness to proinflammatory stimuli and reduced susceptibility to induction of experimental autoimmune encephalomyelitis. Mice treated with FHES had enhanced alternatively activated macrophages, reduced Th1 and Th17 responses, and attenuating effects on autoimmunity that persisted for 8 mo. Furthermore, transplantation of HSCs from FHES-treated mice transferred the anti-inflammatory phenotype to naive mice. Our findings demonstrate that helminth products can modulate HSCs to promote development of anti-inflammatory myeloid cells that attenuate T cell–mediated autoimmune disease. Key Points Helminth products imprint long-term hematopoietic stem cells. Helminth-imprinted hematopoietic stem cells generate anti-inflammatory macrophages. Helminths attenuate autoimmunity by promoting anti-inflammatory trained immunity.
- 1 October 2020
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 205 (7) , 1909-1919
IL-33–Stimulated Murine Mast Cells Polarize Alternatively Activated Macrophages, Which Suppress T Cells That Mediate Experimental Autoimmune Encephalomyelitis
IL-33 is known to promote type 2 immune responses through ST2, a component of the IL-33R complex, expressed primarily on mast cells, Th2 cells, group 2 innate lymphoid cells and regulatory T cells, and to a lesser extent, on NK cells and Th1 cells. Consistent with previous studies, we found that IL-33 polarized alternatively activated macrophages (AAMΦ) in vivo. However, in vitro stimulation of murine bone marrow–derived or peritoneal macrophages with IL-33 failed to promote arginase activity or expression of YM-1 or Retnla, markers of AAMΦ. Furthermore, macrophages have low/no basal expression of ST2. This suggested that alternative activation of macrophages may involve an IL-33–responsive third-party cell. Because mast cells have the highest expression of ST2 relative to other leukocytes, we focused on this cell type. Coculture experiments showed that IL-33–stimulated mast cells polarized AAMΦ through production of soluble factors. IL-33–stimulated mast cells produced a range of cytokines, including IL-6 and IL-13. Mast cell–derived IL-13 was required for induction of AAMΦ, whereas mast cell–derived IL-6 enhanced macrophage responsiveness to IL-13 via upregulation of the IL-4Rα receptor. Furthermore, we found that AAMΦ polarized by IL-33–stimulated mast cells could suppress proliferation and IL-17 and IFN-γ production by T cells. Finally, we show that AAMΦ polarized by IL-33–stimulated mast cells attenuated the encephalitogenic function of T cells in the experimental autoimmune encephalomyelitis model. Our findings reveal that IL-33 can promote immunosuppressive responses by polarizing AAMΦ via mast cell–derived IL-6 and IL-13.
- 1 October 2020
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 205 (7) , 1909-1919
IL-33–Stimulated Murine Mast Cells Polarize Alternatively Activated Macrophages, Which Suppress T Cells That Mediate Experimental Autoimmune Encephalomyelitis
IL-33 is known to promote type 2 immune responses through ST2, a component of the IL-33R complex, expressed primarily on mast cells, Th2 cells, group 2 innate lymphoid cells and regulatory T cells, and to a lesser extent, on NK cells and Th1 cells. Consistent with previous studies, we found that IL-33 polarized alternatively activated macrophages (AAMΦ) in vivo. However, in vitro stimulation of murine bone marrow–derived or peritoneal macrophages with IL-33 failed to promote arginase activity or expression of YM-1 or Retnla, markers of AAMΦ. Furthermore, macrophages have low/no basal expression of ST2. This suggested that alternative activation of macrophages may involve an IL-33–responsive third-party cell. Because mast cells have the highest expression of ST2 relative to other leukocytes, we focused on this cell type. Coculture experiments showed that IL-33–stimulated mast cells polarized AAMΦ through production of soluble factors. IL-33–stimulated mast cells produced a range of cytokines, including IL-6 and IL-13. Mast cell–derived IL-13 was required for induction of AAMΦ, whereas mast cell–derived IL-6 enhanced macrophage responsiveness to IL-13 via upregulation of the IL-4Rα receptor. Furthermore, we found that AAMΦ polarized by IL-33–stimulated mast cells could suppress proliferation and IL-17 and IFN-γ production by T cells. Finally, we show that AAMΦ polarized by IL-33–stimulated mast cells attenuated the encephalitogenic function of T cells in the experimental autoimmune encephalomyelitis model. Our findings reveal that IL-33 can promote immunosuppressive responses by polarizing AAMΦ via mast cell–derived IL-6 and IL-13.